Saint John's Health Center

January 2007

Abraxis CEO, Wife to Give St. John's $35 Million


Santa Monica, CA -- January 15, 2007 -- Saint John's Health Center announced today that in recognition of its outstanding patient care and its commitment to translational medicine, Michele B. Chan, Dr. Patrick Soon-Shiong, and their family have committed $35 million to complete the building of a world class inpatient life science center, and to begin development of a new Center for Translational Sciences. Dr. Soon-Shiong is the founder, president and chief executive officer of Abraxis BioScience.

The Health Center is naming the state-of-the-art inpatient facility the Chan Soon-Shiong Center for Life Sciences, to honor a $25 million grant to Saint John's Challenge to Lead Campaign. An additional $10 million grant will be designated to develop a master plan for its South Campus and the Chan Soon-Shiong Center for Translational Sciences, which will be developed subject to requisite approvals.



2009 The Hospital of the Future - Announcement

October 2009

Pharmaceutical executive donates $100 million to St. John's Health Center

The gift from Patrick Soon-Shiong and his wife is aimed at turning St. John's into a cutting-edge medical hub.


A billionaire Los Angeles pharmaceutical executive bent on creating a national medical data-sharing network has donated $100 million to turn St. John's Health Center in Santa Monica into a cutting-edge hub.

The gift from Patrick Soon-Shiong, founder and chief executive of Los Angeles-based Abraxis BioScience Inc., and his wife, Michele Chan, a former actress, is the hospital's largest donation by an individual and one of the largest received by a community hospital in California. It comes on top of an additional $35 million the couple donated to the hospital two years ago.

About $35 million has been spent on the expanded and renovated 380-bed hospital, and $10 million more to attract doctors and scientists. That leaves $55 million to create several research centers and fund future projects, said St. John's Chief Executive Lou Lazatin.

"It will make St. John's the community hospital of the future," Lazatin said.

For the full report, click here.

Martin Luther King Jr./Charles R. Drew Medical Center

November 2009

Billionaire offers $100-million guaranty to reopen King hospital

The funding from Patrick Soon-Shiong's family foundation would underwrite a University of California effort to resuscitate the medical center near Watts.

Los Angeles pharmaceutical billionaire Patrick Soon-Shiong announced plans Wednesday to provide University of California regents with a $100-million guaranty underwriting the county's latest proposal to reopen long-troubled Martin Luther King Jr.-Harbor Hospital by 2012.

County officials have expressed misgivings about Soon-Shiong's efforts to reopen the hospital in the past. But he said the funding from his family foundation comes "with no strings attached" and is intended to reassure university officials hesitant to reopen the hospital.

"This could be the county hospital of the future," said Soon-Shiong, 57, a former UCLA surgeon.

For the full report, click here.

Today in LA 2009 - The Chan Soon-Shiong Family Foundation agreed to provide a $100 million underwriting guarantee to help reopen the hospital in 2012 under management by the University of California.
Jan 15, 2010 - Martin Luther King Jr. Labor Breakfast - The Los Angeles County Federation of Labor recognizes Dr. Patrick Soon-Shiong for his commitment to helping keep the dream alive.

Additional Coverage:


NANTNew Approaches to Neuroblastoma Therapy

What is NANT? The NANT consortium offers hope and resources to patients and their families with relapsed/refractory neuroblastoma when front-line, standard therapy fails. Established in 2000, NANT is the only consortium in the world solely dedicated to developing novel treatments and biomarkers through early clinical trials (Phase I/II) for children whose disease has become resistant to front-line therapies. NANT addresses the most difficult but most relevant question for children with high-risk neuroblastoma: "What is the best strategy to attack this disease when it has escaped all standard front-line therapies?" NANT believes that a comprehensive approach that targets the cancer cells but also their surrounding environment by a team of researchers with converging expertise will make a difference.

Our vision is to develop and test new therapies that target both neuroblastoma cells and normal cells around the tumor and in the immune system to improve the outcome for children with high-risk neuroblastoma with fewer side effects.

Phoenix Children's Hospital

October 2014

Phoenix Children’s Hospital and Chan Soon-Shiong Institute of Molecular Medicine partner to bring faster genomic sequencing and personalized therapies to young patients

PHOENIX (Oct. 3, 2014) – Dr. Patrick Soon-Shiong joined Phoenix Children’s Hospital today to announce the formation of a visionary institute, The Chan Soon-Shiong Children’s Precision Medicine Institute at Phoenix Children’s Hospital.

The new partnership brings together the medical expertise and resources of renowned surgeon and health care technology visionary Patrick Soon-Shiong, MD, with Phoenix Children’s commitment to genomic research and access to a large pediatric patient base. The institute will transform the pediatric health care landscape by applying state-of-the-art genomic and proteomic technology to identify precision diagnoses, treatments and cures for young patients facing serious illnesses.

For the full report, click here.

Martin Luther King Hospital Dedication and Opening

August 2015

Read More:  Los Angeles TImes

Read More: 
Los Angeles TImes

Windber Medical Center

August 2015

The Chan Soon-Shiong Windber Institute of Molecular Medicine Established with the Integration of Windber Medical Center and Windber Research Institute

WINDBER, Pa. & CULVER CITY, Calif.--(BUSINESS WIRE)--August 14, 2015--Windber Medical Center (WMC) and Windber Research Institute (WRI) have entered into definitive agreements with the Chan Soon-Shiong Institute of Molecular Medicine, (CSSIOMM), a nonprofit medical research organization founded by Dr. Patrick Soon-Shiong and his wife, Michele Chan, to establish an integrated community based health care organization delivering 21st century care.

“Dr. Soon-Shiong is a visionary at the forefront of transforming health care in the U.S. and around the world through research, technology and integrated communication” — Tom Kurtz, CEO of WMC and WRI
“Dr. Soon-Shiong is a visionary at the forefront of transforming health care in the U.S. and around the world through research, technology and integrated communication”

— Tom Kurtz, CEO of WMC and WRI

The agreements include the creation of a precision cancer research and treatment institute at WMC and WRI. The vision for WMC and WRI is to become dedicated molecular medicine and genomic research institutions and centers of excellence for studying cancer and other diseases. WMC and WRI will remain non-profit institutions with WMC continuing its mission as an acute care community hospital and retaining its existing service lines. Regional and national clinical delivery partnerships with major health systems are under discussion.

For the full report, click here.

Community Oncology Supergroup: Quality Cancer Care Alliance (QCCA)

September 2015

Quality Cancer Care Alliance Aligns Leading Community Oncology Practices in Commitment to Patient-Centered Care and Clinical Trials

“The group plans to work with many stakeholders in the cancer community that share the vision of improving clinical outcomes and the cancer care delivery system.” — Ray Page, D.O., Ph.D., Center for Cancer and Blood Disorders in Fort Worth, TX
“The group plans to work with many stakeholders in the cancer community that share the vision of improving clinical outcomes and the cancer care delivery system.”

— Ray Page, D.O., Ph.D., Center for Cancer and Blood Disorders in Fort Worth, TX

September 10, 2015--A number of progressive, independent community oncology practices located throughout the nation have formed a professional alliance, the Quality Cancer Care Alliance (QCCA), to improve the treatment of cancer patients and to bring a broad range of clinical trials to their communities. One of the founding physicians of QCCA, Sibel Blau, MD of Northwest Medical Specialties said, “Patients deserve our best efforts to bring high quality, high value oncology care and clinical research to them in their hometowns.”

As the group’s name indicates, these oncology practices are focused on providing the highest quality care to patients in their respective communities. QCCA plans to achieve its objectives by:

  • sharing best practices for process and treatment improvement,
  • collaborating to create innovative approaches to improve patient care,
  • adhering to value-based cancer care guidelines, and
  • providing patients local access to transformative clinical trial designs.

QCCA will offer clinical trials based on personalized tumor signatures that are expected to change the treatment paradigm by allowing physicians to choose novel targeted therapies and clinical trials based on the individual profile of the patient’s disease. The goal is to help physicians quickly identify the optimal treatments for specific disease processes. The ability to share real-time information about the best treatments and clinical trials among the practices allows patients in community settings to benefit from the very latest knowledge.

For the full report, click here.

Cancer Breakthroughs 2020

January 2016

Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer

Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer Breakthroughs 2020 Program

  • Nation’s first insurance coverage of next generation whole genome sequencing and proteomic diagnostic platform in cancer patients

  • Next generation sequencing and precision medicine evolving from research to the clinical trial and cancer care setting

  • Coalition to design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple phase 1 to 3 trials by year 2020

  • Beneficiaries and patients will undergo next-generation molecular sequencing and gain access to over 60 novel and approved molecules to be tested as immunotherapy combinations in 20,000 cancer patients with cancer across all tumor types: The QUILT Program